These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21394662)

  • 1. Impact of obesity on operative morbidity and clinical outcome in primary epithelial ovarian cancer after optimal primary tumor debulking.
    Fotopoulou C; Richter R; Braicu EI; Kuhberg M; Feldheiser A; Schefold JC; Lichtenegger W; Sehouli J
    Ann Surg Oncol; 2011 Sep; 18(9):2629-37. PubMed ID: 21394662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of obesity on survival in patients with ovarian cancer.
    Matthews KS; Straughn JM; Kemper MK; Hoskins KE; Wang W; Rocconi RP
    Gynecol Oncol; 2009 Feb; 112(2):389-93. PubMed ID: 19062080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns.
    Park JY; Seo SS; Kang S; Lee KB; Lim SY; Choi HS; Park SY
    Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome.
    Salani R; Santillan A; Zahurak ML; Giuntoli RL; Gardner GJ; Armstrong DK; Bristow RE
    Cancer; 2007 Feb; 109(4):685-91. PubMed ID: 17219441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?
    Zang RY; Li ZT; Tang J; Cheng X; Cai SM; Zhang ZY; Teng NN
    Cancer; 2004 Mar; 100(6):1152-61. PubMed ID: 15022281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body mass index and survival in patients with epithelial ovarian cancer.
    Suh DH; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Kang SB
    J Obstet Gynaecol Res; 2012 Jan; 38(1):70-6. PubMed ID: 21827578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Body mass index as a prognostic factor in epithelial ovarian cancer and correlation with clinico-pathological factors.
    Skírnisdóttir I; Sorbe B
    Acta Obstet Gynecol Scand; 2010; 89(1):101-7. PubMed ID: 19878086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
    Fotopoulou C; Zang R; Gultekin M; Cibula D; Ayhan A; Liu D; Richter R; Braicu I; Mahner S; Harter P; Trillsch F; Kumar S; Peiretti M; Dowdy SC; Maggioni A; Trope C; Sehouli J
    Ann Surg Oncol; 2013 Apr; 20(4):1348-54. PubMed ID: 23054114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer.
    Kommoss S; Rochon J; Harter P; Heitz F; Grabowski JP; Ewald-Riegler N; Haberstroh M; Neunhoeffer T; Barinoff J; Gomez R; Traut A; du Bois A
    Ann Surg Oncol; 2010 Jan; 17(1):279-86. PubMed ID: 19898901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
    Chi DS; Eisenhauer EL; Lang J; Huh J; Haddad L; Abu-Rustum NR; Sonoda Y; Levine DA; Hensley M; Barakat RR
    Gynecol Oncol; 2006 Nov; 103(2):559-64. PubMed ID: 16714056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of obesity on survival in epithelial ovarian cancer.
    Pavelka JC; Brown RS; Karlan BY; Cass I; Leuchter RS; Lagasse LD; Li AJ
    Cancer; 2006 Oct; 107(7):1520-4. PubMed ID: 16941453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.
    Eisenkop SM; Friedman RL; Wang HJ
    Gynecol Oncol; 1998 May; 69(2):103-8. PubMed ID: 9600815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience.
    Peiretti M; Zanagnolo V; Aletti GD; Bocciolone L; Colombo N; Landoni F; Minig L; Biffi R; Radice D; Maggioni A
    Gynecol Oncol; 2010 Nov; 119(2):259-64. PubMed ID: 20800269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
    Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.
    Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Poynor EA; Aghajanian C; Jarnagin WR; DeMatteo RP; D'Angelica MI; Barakat RR; Chi DS
    Gynecol Oncol; 2006 Dec; 103(3):1083-90. PubMed ID: 16890277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer.
    Munkarah AR; Hallum AV; Morris M; Burke TW; Levenback C; Atkinson EN; Wharton JT; Gershenson DM
    Gynecol Oncol; 1997 Jan; 64(1):13-7. PubMed ID: 8995541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer.
    Aletti GD; Dowdy SC; Podratz KC; Cliby WA
    Gynecol Oncol; 2006 Feb; 100(2):283-7. PubMed ID: 16182350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.